Pediatric Micafungin

 

This reference library was created for the community of providers who care for children with these illnesses. It was developed to assist clinicians in understanding, diagnosing and treating pediatric invasive fungal infections. The library links to important references within each category but is not meant to be comprehensive. 

 

Return to Library Home

 

 

 

 

 

 

 

 

 

 

International Pediatric Fungal Network, Box 3499, Duke University Medical Center, Durham, NC 27710. USA.   Tel: 919-668-4847 Email: PFNContracts@duke.edu

Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. 

Wiederhold NP et al. Infect Drug Resist. 2008;1:63-77. Epub 2009 Jan 12.

Breakthrough invasive candidiasis in patients on micafungin. 

Pfeiffer CD et al. J Clin Microbiol. 2010 Jul;48(7):2373-80.

Review of the pharmacology and clinical studies of micafungin. 

Bormann AM et al. Drug Des Devel Ther. 2009 Dec 29;3:295-302.

Safety of micafungin in infants: Insights into optimal dosing. 

Ascher S et al. Expert Opin Drug Saf. 2011 Mar;10(2):281-6.

Population pharmacokinetics of micafungin in neonates and young infants. 

Hope WW et al. Antimicrob Agents Chemother. 2010 Jun;54(6):2633-7.

Safety and pharmacokinetics of repeat-dose micafungin in young infants. 

Benjamin DK Jr et al. Clin Pharmacol Ther. 2010 Jan;87(1):93-9.

Micafungin versus fluconazole for prophylaxis against fungal infections in premature infants.

Maede Y et al. Pediatr Int. 2013 Jun 17. doi: 10.1111/ped.12157. 

Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: a multicenter prospective study. 

Kobayashi R et al. J Pediatr Hematol Oncol. 2013 Oct;35(7):e276-9.

Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. 

Undre NA et al. Pediatr Infect Dis J. 2012 Jun;31(6):630-2.

Micafungin use in children. 

Emiroglu M et al. Expert Rev Anti Infect Ther. 2011 Sep;9(9):821-34.

Safety of micafungin in pediatric clinical trials. 

Arrieta AC et al. Pediatr Infect Dis J. 2011 Jun;30(6):e97-e102.

Alternate-day micafungin antifungal prophylaxis in high risk pediatric patients undergoing hematopoietic cell transplantation: a pharmacokinetic study. 

Mehta PA et al. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62.

Micafungin: A brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. 

Lehrnbecher T et al. Pediatr Blood Cancer. 2010 Aug;55(2):229-32.

Optimizing micafungin dosing in children. 

Zhao W et al. Pediatr Infect Dis J. 2012 Nov;31(11):1211-2; author reply 1212.

Pharmacokinetics of an elevated dosage of micafungin in premature neonates. 

Smith et al. Pediatr Infect Dis J. 2009 May;28(5):412-5.

Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. 

Undre NA et al. Pediatr Infect Dis J. 2012 Jun;31(6):630-2.

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. 

Hope WW et al. Antimicrob Agents Chemother. 2007 Oct;51(10):3714-9. Epub 2007 Jul 16.